afatinib + loperamide

Afatinib + loperamide is a non-fixed combination therapy used in the management of non-small cell lung cancer (NSCLC) where afatinib, an irreversible ErbB family blocker and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is administered as an anticancer agent. Loperamide, a peripherally acting μ-opioid receptor agonist, is co-administered to manage or prevent diarrhea—a common and sometimes severe adverse effect of afatinib therapy. Afatinib inhibits EGFR signaling pathways involved in tumor proliferation and survival. Loperamide acts on intestinal opioid receptors to reduce gut motility and fluid secretion without central nervous system effects at recommended doses. This combination does not represent a single pharmaceutical product but rather a clinical practice approach for supportive care during cancer treatment[1][4][5][6].

Brand names

Gilotrif (afatinib)Imodium (loperamide)

Other names

afatinib and loperamide combinationafatinib plus loperamide